Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,112 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypersensitivity, Immediate Clear all

Conditions: Asthma
Interventions: Project ASPIRE Home-Based Family Intervention, Project ASPIRE Enhanced Treatment As Usual; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 8 Years to 13 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Atlanta, Georgia • Smyrna, Georgia

Conditions: Asthma
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions: Home hospital care; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Asthma, Atherosclerosis, Metabolic Syndrome, Insulin Resistance, Cancer
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 725 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Peanut Allergy
Interventions: Dupilumab, Placebo matching dupilumab, AR101; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 25
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 21 more

Conditions: Asthma
Interventions: GW685698X, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 94
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 81 more

Conditions: Atopic Dermatitis
Interventions: NM26-2198, Placebo; Biological · Other
Lead sponsor: Yellow Jersey Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Fountain Valley, California • Glendale, California • San Diego, California + 3 more

Conditions: Infections, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulation, Diabetes and Its Complications, End of Life/Desires Only Medical Management
Interventions: Home Hospital care, Traditional Hospital care; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Quincy, Illinois • Hazard, Kentucky

Conditions: Hypersensitivity Pneumonitis
Interventions: Re-imagining Interventions for Support and Education in Hypersensitivity Pneumonitis (RISE-HP), Staying Well; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: Not listed
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Allergy and Asthma
Interventions: Not listed
Lead sponsor: Mead Johnson Nutrition; Industry
Eligibility: 3 Years to 7 Years
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Asthma
Interventions: tiotropium bromide, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 5
States / cities: Denver, Colorado • Columbia, Missouri • Warrensburg, Missouri + 2 more

Conditions: Asthma
Interventions: Not listed
Lead sponsor: 59th Medical Wing; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Eosinophilic Esophagitis
Interventions: SECM Capsule; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 14 Years and older
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Food Allergy, Peanut Allergy
Interventions: Peanut Protein, Continued peanut avoidance; Biological · Other
Lead sponsor: Scott Sicherer; Other
Eligibility: 4 Years to 14 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Hereditary Angioedema
Interventions: NTLA-2002, Normal Saline IV Administration; Biological
Lead sponsor: Intellia Therapeutics; Industry
Eligibility: 16 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 14
States / cities: Scottsdale, Arizona • San Diego, California • Santa Monica, California + 11 more

Conditions: Asthma
Interventions: Placebo, RO4989991; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: South Miami, Florida • Normal, Illinois • Raleigh, North Carolina + 1 more

Conditions: Chronic Idiopathic Urticaria
Interventions: Placebo, Omalizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 36
States / cities: La Jolla, California • Los Angeles, California • Redwood City, California + 31 more

Conditions: Gastroesophageal Reflux, Asthma
Interventions: lansoprazole, placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Atopic Dermatitis
Interventions: Dupilumab, Photo therapy; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Atopic Dermatitis
Interventions: Cetaphil Restoraderm, Standard of Care; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 1 Day to 3 Weeks
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Allergic Conjunctivitis
Interventions: Ketotifen/naphazoline, Ketotifen, Naphazoline, Vehicle; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 6 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: North Andover, Massachusetts

Conditions: Peanut Allergies, Tree Nut Allergies, Other Food Allergies
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 1 Year to 75 Years
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2030
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Asthma
Interventions: fluticasone; Drug
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 12 Years to 69 Years
Enrollment: 219 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 13
States / cities: San Diego, California • Jacksonville, Florida • Miami, Florida + 10 more

Search by objective public record fields.

Family-Focused, Stress-Reduction Program to Improve the Health Care of Urban Children With Asthma

Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology

Rural Home Hospital: Proof of Concept

Study of the Effect of Innate on the Inflammatory Response to Endotoxin

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.

Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)

Rural Hospital-Level Care at Home for Acutely Ill Adults

Reimagining Interventions for Support and Education in Hypersensitivity Pneumonitis

Creation of Home-based Asthma Real-World Measures With Mobile Health Study

Allergy and Ashthma in Children Who Were Fed Supplemented Infant Formula

Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma

Levels of Serum Resistin in Asthmatics as a Potential Marker of Systemic Inflammation and Disease State.

Using Spectrally Encoded Confocal Microscopy (SECM) to Image the Esophagus

Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

A Study of RO4989991 in Patients With Allergic Rhinitis

A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)

Elucidation of Acid-Induced Pulmonary Inflammation

IL-4 and Insulin Resistance for Treatment of Patients With Atopic Dermatitis

Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.

Blood Samples for the Study of Peanut, Tree Nut and Other Food Allergies

MethaCholine Bronchoprovocation Study (MeCIS)